Business Activities

Research and Development

Research

Mochida's Research Center - targeting diabetes and obesity as its core fields and chronic pain as another important field of study - is immersed in efforts to discover and synthesize promising low-molecular weight compounds, using state-of-the-art computer-screening, high-throughput screening, and other advanced methods.

Development

Mochida Pharmaceutical's product development pipelines offer lineups that will greatly enhance our major specialities: cardiovascular medicine, obstetrics and gynecology, dermatology, emergency medicine, and psychiatry. We remain ever committed to the efficient development of new and widely hoped-for therapeutic drugs, to be put to medical use as soon as is safely possible.

Pipeline

As of October 28,2013
Code Name Indications Formulation Stage Remarks
AJH801 cilnidipine/
valsartan combination
Hypertension Oral Filed Co-development with Ajinomoto Pharmaceuticals
MD-0701 treprostinil Pulmonary arterial hypertension Injection Filed Originator: United Therapeutics
(USA)
MD-0901 mesalazine Ulcerative colitis Oral Phase III Licensed-in from Shire Pharmaceuticals Group
(UK)
MLD-55 escitalopram Social anxiety disorder Oral Phase III Licensed-in from Lundbeck (Denmark)
MND-21 ethyl
icosapentate
Non-alcoholic steatohepatitis Oral Phase II completed  
MJR-35 dienogest Uterine adenomyosis Oral Late Phase II Licensed-in from Jenapharm (Bayer Pharma AG)
MTD-39 imiquimod common warts Topical Early Phase II Licensed-in from iNova Pharmaceuticals